Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauricio Tohen

Showing results (51-60 of 260) with videos related to

Pageof 26
Sort By:
Journal of Affective Disorders|June 22, 2007
Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational studyEduard Vieta, Francesco Panicali, Iris Goetz, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 28, 2020
The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature ReviewLeona Bessonova, Kristine Ogden, Michael J Doane, et al.
Current Medical Research and Opinion|February 24, 2012
Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorderHideaki Katagiri, Yasushi Takita, Mauricio Tohen, et al.
The Journal of Clinical Psychiatry|January 12, 2005
Weight gain during treatment of bipolar I patients with olanzapineJohn Hennen, Roy H Perlis, Gary Sachs, et al.
The International Journal of Neuropsychopharmacology|February 5, 2010
Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysisJorge M Tamayo, Carlos A Zarate, Eduard Vieta, et al.
Neuropsychiatric Disease and Treatment|February 24, 2021
Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature ReviewMichael J Doane, Kristine Ogden, Leona Bessonova, et al.
Journal of Affective Disorders|December 3, 2011
Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled studyHideaki Katagiri, Yasushi Takita, Mauricio Tohen, et al.
Current Medical Research and Opinion|May 26, 2021
The efficacy of cariprazine on function in patients with bipolar depression: a <i>post hoc</i> analysis of a randomized controlled trialEduard Vieta, Joseph R Calabrese, Jessica Whelan, et al.
Journal of Affective Disorders|October 29, 2005
Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week dataTrisha Suppes, Eileen Brown, Leslie M Schuh, et al.
The Journal of Clinical Psychiatry|April 5, 2011
Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidoneDavid E Kemp, Ellyn Johnson, Wei V Wang, et al.
Pageof 26

Showing results (51-60 of 260) with videos related to

Sort By:
Pageof 26
Journal of Affective Disorders|June 22, 2007
Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational studyEduard Vieta, Francesco Panicali, Iris Goetz, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 28, 2020
The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature ReviewLeona Bessonova, Kristine Ogden, Michael J Doane, et al.
Current Medical Research and Opinion|February 24, 2012
Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorderHideaki Katagiri, Yasushi Takita, Mauricio Tohen, et al.
The Journal of Clinical Psychiatry|January 12, 2005
Weight gain during treatment of bipolar I patients with olanzapineJohn Hennen, Roy H Perlis, Gary Sachs, et al.
The International Journal of Neuropsychopharmacology|February 5, 2010
Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysisJorge M Tamayo, Carlos A Zarate, Eduard Vieta, et al.
Neuropsychiatric Disease and Treatment|February 24, 2021
Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature ReviewMichael J Doane, Kristine Ogden, Leona Bessonova, et al.
Journal of Affective Disorders|December 3, 2011
Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled studyHideaki Katagiri, Yasushi Takita, Mauricio Tohen, et al.
Current Medical Research and Opinion|May 26, 2021
The efficacy of cariprazine on function in patients with bipolar depression: a <i>post hoc</i> analysis of a randomized controlled trialEduard Vieta, Joseph R Calabrese, Jessica Whelan, et al.
Journal of Affective Disorders|October 29, 2005
Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week dataTrisha Suppes, Eileen Brown, Leslie M Schuh, et al.
The Journal of Clinical Psychiatry|April 5, 2011
Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidoneDavid E Kemp, Ellyn Johnson, Wei V Wang, et al.
Pageof 26